Tolaney Sara M, Shaw Lindsay
Dana-Farber Cancer Institute, Boston, Massachusetts.
J Adv Pract Oncol. 2022 Apr;13(3):298-301. doi: 10.6004/jadpro.2022.13.3.23. Epub 2022 May 23.
At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the current treatment landscape, for metastatic triple-negative breast cancer. Dr. Tolaney and Ms. Shaw also discussed principles of monitoring and managing adverse events associated with immunotherapies.
在2021年JADPRO现场虚拟会议上，医学博士、公共卫生硕士萨拉·M·托拉尼和高级执业护士、认证肿瘤学高级执业护士林赛·肖介绍了已获批的免疫检查点抑制剂和抗体药物偶联物的近期临床试验数据，以及它们在转移性三阴性乳腺癌当前治疗格局中的意义。托拉尼博士和肖女士还讨论了监测和管理与免疫疗法相关不良事件的原则。
